webinar register page

Webinar banner
Pharma - Solid Tumor Cancers
What is the state of progress in extending cell-based gene therapies to fight solid tumor cancers? How successful has the pharma industry been in building new therapeutic and diagnostic platforms to fight major cancers and address their prevalence in vulnerable populations, including the aged, minorities, and pediatric patients?

Oct 26, 2022 12:00 PM in Eastern Time (US and Canada)

Webinar logo
* Required information


Dr. Greg Friberg
VP Medical Affairs, ELMAC Region @Amgen, Inc.
Greg serves as Vice President, Medical Affairs for Europe, Latin America, Middle East, Africa, and Canada (the ELMAC Region), having taken on the role in the Summer of 2021. Greg joined Amgen in Medical Sciences in 2006, first serving as an early development lead and then as Oncology Therapeutic Area (TA) head for the early pipeline. Starting in 2014, Greg served as the interim Global Development co-TA head for Oncology, overseeing the initial regulatory approvals for blinatumomab and talimogene laherparepvec. He then served as Global Product General Manager for blinatumomab and the early hematology BiTE portfolio. In 2018, Greg became the Global Development TA Head for Hematology/Oncology and Bone. He helped build the development team over the next 4 years and to usher romosozumab, blinatumomab for MRD, and sotorasib to their first approvals. Of note, sotorasib was the first KRAS G12C inhibitor approved in the US, with under three years from first patient dosed to FDA approval.
Blueprint Medicines Inc.
Deciphera Pharmaceuticals
Mark Cornfeld, MD, MPH
Vice President, Hematology Oncology Clinical Development @Incyte Corp.
Mark Cornfeld is the Vice President of Hematology Oncology Clinical Development at lncyte. With over 20 years of experience in the biopharma industry, since 2017 he has served as the lead physician for the clinical development of lncyte’s immuno-oncology (10) assets, such as its PD-1 inhibitor. He also leads related external partnering and relationship management. At Incyte, Mark created the development vision for multiple products and initiated clinical trials designed for accelerated and full approval in multiple indications. He also developed product-specific protocol language, patient management guidelines and data collection standards to help maintain quality clinical research at the company. Through his leadership, Mark helped build a high- performing, experienced clinical team to help Incyte advance its portfolio of oncology medicines. Prior, Mark held various positions in the biopharma industry, with a focus on early- and late-stage R&D, global regulatory and medical affairs.
Dr. Sylvie Laquerre
Vice President, Disease Area Leader, Solid Tumor Targeted Therapies @Janssen Pharmaceuticals
Sylvie Laquerre, Ph.D. is Vice President, Solid Tumor Targeted Therapy (ST3) Disease Area Stronghold (DAS), Oncology Therapeutic Area, Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. In this role, Dr. Laquerre is responsible for the strategic direction and execution of the ST3 DAS portfolio from early drug discovery efforts through clinical development. During her tenure at Janssen, Dr. Laquerre advanced strong discovery and translational research to deliver a robust preclinical and clinical pipeline of novel targeted agents and immuno-stimulatory biologics. She contributed to discovery, development and approval of Balversa (FGFR inhibitor) and Rybrevant (Bispecific EGFR/cMET antibody). Dr. Laquerre also contributed to multiple key collaborations and acquisitions to enhance the Janssen’s R&D portfolio.
Myovant Sciences GmbH
Patrice A. Lee, PhD
Vice President, Pharmacology, Toxicology and Exploratory Development @Pfizer, Inc.
Patrice Lee, Ph.D. is Vice President (VP) Pharmacology, Toxicology and Exploratory Development at the Pfizer Boulder Research & Development facility primarily focused on the discovery and development of targeted small molecule drugs that have the potential to treat patients afflicted by cancer and other life-threatening diseases. Specifically, her team is responsible for demonstrating the therapeutic activity of these drugs, assessing safety and working with the early Clinical Development team to move these drugs into the clinical rapidly to help patients. Prior to the acquisition of Array BioPharma, Inc. by Pfizer in July, 2019, Dr. Lee held various leadership positions at Array BioPharma since February 2003. She is a scientific leader with 30 years of experience in pharmaceutical, medical device and biotechnology research and development, with expertise in discovery research, regulated safety studies and clinical development.
Seagen Inc.
Dr. Sanjay Srivastava (Moderator)
Managing Director, Cell & Gene therapy lead @Accenture
Sanjay has a broad and deep expertise in the underpinning science and business challenges in developing and launch-ing both in-vivo and ex-vivo cell & gene therapies. He directs his C&GT team at Accenture, who has global expertise in R&D, supply chain, manufacturing, and commercial operations.